ImmuPharma PLC - Asset Resilience Ratio

Latest as of December 2023: 0.00%

ImmuPharma PLC (IMM) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is ImmuPharma PLC's working capital to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

GBX-1.00

≈ $-0.00 USD Cash + Short-term Investments

Total Assets

GBX2.72 Million

≈ $331.12 USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2022)

This chart shows how ImmuPharma PLC's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of ImmuPharma PLC.

Liquid Assets Composition Over Time

This chart breaks down ImmuPharma PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore long-term investment intensity of ImmuPharma PLC to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	GBX0.00	0%
Short-term Investments	GBX-1.00	-0.0%
Total Liquid Assets	GBX-1.00	0.00%

Asset Resilience Insights

Limited Liquidity: ImmuPharma PLC maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

ImmuPharma PLC Industry Peers by Asset Resilience Ratio

Compare ImmuPharma PLC's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Abivax SA PA:ABVX	Biotechnology	2.58%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Lifecome Biochemistry Co Ltd SHE:002868	Biotechnology	4.69%
Pulike Biological Engineering SHG:603566	Biotechnology	17.82%
Rocket Pharmaceuticals Inc NASDAQ:RCKT	Biotechnology	14.00%
NEWRON PHARMACEUT. EO-20 XETRA:NP5	Biotechnology	41.67%
Upstream Bio, Inc. NASDAQ:UPB	Biotechnology	64.70%

Annual Asset Resilience Ratio for ImmuPharma PLC (2016–2022)

The table below shows the annual Asset Resilience Ratio data for ImmuPharma PLC.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	-2.08%	GBX-82.56K ≈ $-10.05	GBX3.97 Million ≈ $483.61	+4.68pp
2021-12-31	-6.76%	GBX-405.49K ≈ $-49.34	GBX6.00 Million ≈ $729.76	-5.16pp
2020-12-31	-1.60%	GBX-174.49K ≈ $-21.23	GBX10.92 Million ≈ $1.33K	+12.94pp
2019-12-31	-14.53%	GBX-843.15K ≈ $-102.59	GBX5.80 Million ≈ $705.82	-37.71pp
2016-12-31	23.17%	GBX1.55 Million ≈ $189.18	GBX6.71 Million ≈ $816.39	--

pp = percentage points

About ImmuPharma PLC

LSE:IMM UK Biotechnology

Market Cap

$223.87K

GBX1.84 Billion GBX

Market Cap Rank

#31314 Global

#1021 in UK

Share Price

GBX3.66

Change (1 day)

-3.81%

52-Week Range

GBX3.21 - GBX13.00

All Time High

GBX190.00